Results 171 to 180 of about 615,884 (310)

MMP2‐Responsive Liposomes Targeting LDLR Enhance the Effectiveness of Anti‐Cancer Drugs in Treating Melanoma

open access: yesAdvanced Therapeutics, EarlyView.
A bi‐functional liposomal system is developed to enhance melanoma therapy, combining mApoE‐mediated targeting of LDLR‐expressing tumor cells with MMP2‐responsive drug release. Loaded with Pimasertib, the liposomes improve intracellular delivery, reduce melanoma viability, and inhibit 3D spheroid growth and invasiveness.
Antonio Renda   +14 more
wiley   +1 more source

Phase‐Separation of YAP Mediates AJUBA Super Enhancer Activation to Promote Aberrant Mitosis in Breast Cancer

open access: yesAdvanced Science, EarlyView.
YAP undergoes phase separation to activate the AJUBA super‐enhancer, driving aberrant mitosis through spindle checkpoint dysregulation in breast cancer. This study uncovers a mechanistic link between YAP condensates, super‐enhancer activation, and aneuploidy formation.
Rui Zhang   +8 more
wiley   +1 more source

Obesity‐Associated TRIM15 Promotes the Proliferation of Esophageal Adenocarcinoma Through the YY2/FOXRED1 Axis

open access: yesAdvanced Science, EarlyView.
The study identifies TRIM15 as a key driver in the development of obesity‐associated esophageal adenocarcinoma (EAC). Mechanistically, TRIM15 degrades YY2 through the proteasome pathway, suppressing FOXRED1 transcription and ultimately accelerating tumor proliferation.
Haohui Wang   +10 more
wiley   +1 more source

Minimally Invasive Chemical Biopsy Needle with Self‐Wettable Extraction Phase For In Vivo Tissue Sampling During Medical Procedures

open access: yesAdvanced Science, EarlyView.
A new tissue sampling device using an acupuncture needle with bio‐compatible extraction sorbents in the recessed section is developed. The coating material using self‐wettable particles doesn't require solvent activation after sterilization. This device is applied for the anti‐cancer drug concentration monitoring during the in vivo lung perfusion ...
Runshan Will Jiang   +9 more
wiley   +1 more source

Cancer Immunotherapy via Disruption of Integrin αvβ3 and CD47 Costabilization on Cancer Cell Surface

open access: yesAdvanced Science, EarlyView.
This study identifies a cancer‐specific interaction between CD47 and integrin αvβ3 that facilitates immune evasion. A rationally designed peptide, PSFL‐NK13, disrupts this axis, enhancing macrophage‐mediated phagocytosis and suppressing tumor growth without inducing anemia.
Peng‐Cheng Yu   +12 more
wiley   +1 more source

Predicting Immunotherapy Outcomes in NSCLC Using RNA and Pathology from Multicenter Clinical Trials

open access: yesAdvanced Science, EarlyView.
LIRA, a machine learning‐based model, is developed using transcriptomic data from 891 NSCLC patients in the OAK and POPLAR cohorts. Its predictive performance is validated in multiple external cohorts. Patients stratified by LIRA‐score exhibit distinct clinical characteristics and tumor microenvironment profiles.
Zhaojun Wang   +32 more
wiley   +1 more source

Replacing BPA: Structural Substitutes BPAF Binding to the Progesterone Receptor Elevates Breast Cancer Risk

open access: yesAdvanced Science, EarlyView.
This study demonstrates that bisphenol analogues, particularly BPAF, bind to progesterone receptor, promoting breast cancer cell proliferation, migration, and mammary tumor growth, indicating that bisphenol A substitutes may pose equal or greater health risks.
Xiaotong Ji   +8 more
wiley   +1 more source

NNMT Orchestrates Metabolic‐Epigenetic Reprogramming to Drive Macrophage‐Myofibroblast Transition in Hypertrophic Scarring

open access: yesAdvanced Science, EarlyView.
In macrophage‐myofibroblast transition, upregulated NNMT depletes S‐Adenosylmethionine‌ (SAM) and nicotinamide adenine dinucleotide(NAD+), thereby triggering epigenetic reprogramming via Histone H3 Lysine 27 acetylation (H3K27ac) accumulation at the promoter region of master transcription factor Prrx1.
Xiwen Dong   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy